Nrx pharmaceuticals, inc. (nasdaq:nrxp) announces it has filed an application with nasdaq to uplist to the nasdaq global market from the nasdaq capital market

Management believes uplisting has the potential to provide shareholders with improved liquidity requires nrx pharmaceuticals to meet certain listing requirements company has advised nasdaq that current shares outstanding is 15.7 million wilmington, del. , jan. 13, 2025 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx", the "company"), a clinical-stage biopharmaceutical company, today announced it has applied to nasdaq to uplist the company's securities to the nasdaq global market (nasdaq gm).
NRXP Ratings Summary
NRXP Quant Ranking